The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Author:

Van Cutsem Eric,Mayer Robert J.,Laurent StéphanieORCID,Winkler Robert,Grávalos Cristina,Benavides Manuel,Longo-Munoz Federico,Portales Fabienne,Ciardiello Fortunato,Siena Salvatore,Yamaguchi Kensei,Muro Kei,Denda Tadamichi,Tsuji Yasushi,Makris Lukas,Loehrer Patrick,Lenz Heinz-Josef,Ohtsu Atsushi

Funder

Taiho Oncology, Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models;Tanaka;Oncol Rep,2014

2. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA;Sakamoto;Int J Oncol,2015

3. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells;Emura;Int J Mol Med,2004

4. Potentiation of the antitumor activity of α, α, α-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo;Emura;Int J Oncol,2005

5. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3